Skip to main content

Table 2 Association of anti-PD1 with clinical features of new-onset SLE patients

From: Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients

Clinical manifestations

p value

Odds ratio

95% CI

Malar rash

0.001

15.773

3.065–81.186

Discoid rash

0.077

12.688

0.762–211.274

Arthritis

<0.001

22.937

4.619–113.9

Oral ulcer

0.279

3.830

0.336–43.256

Photosensitivity

0.477

4.042

0.086–189.971

Vasculitis

0.216

4.851

0.398–59.109

Raynaud’s phenomenon

0.657

2.266

0.061–84.212

Serositis

0.007

16.008

2.119–120.967

Hematological involvement

<0.001

35.187

6.459–191.679

Renal involvement

0.024

8.306

1.323–52.132

Neurological involvement

0.027

37.282

1.497–928.697

  1. PD-1 programmed cell death protein 1, SLE systemic lupus erythematosus